IL280000A - Tumor reduction formulations and methods of use thereof - Google Patents
Tumor reduction formulations and methods of use thereofInfo
- Publication number
- IL280000A IL280000A IL280000A IL28000021A IL280000A IL 280000 A IL280000 A IL 280000A IL 280000 A IL280000 A IL 280000A IL 28000021 A IL28000021 A IL 28000021A IL 280000 A IL280000 A IL 280000A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- tumor reduction
- formulations
- reduction formulations
- tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862695613P | 2018-07-09 | 2018-07-09 | |
PCT/US2019/040264 WO2020023191A1 (en) | 2018-07-09 | 2019-07-02 | Tumor reduction formulations and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL280000A true IL280000A (en) | 2021-03-01 |
Family
ID=75267393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL280000A IL280000A (en) | 2018-07-09 | 2021-01-07 | Tumor reduction formulations and methods of use thereof |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3820482A4 (en) |
JP (1) | JP2021530482A (en) |
KR (1) | KR20220098082A (en) |
CN (1) | CN112584841A (en) |
AU (1) | AU2019309757A1 (en) |
BR (1) | BR112021000279A8 (en) |
CA (1) | CA3105717A1 (en) |
EA (1) | EA202190201A1 (en) |
IL (1) | IL280000A (en) |
PH (1) | PH12021550033A1 (en) |
WO (1) | WO2020023191A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3140042A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
CA3164190A1 (en) * | 2019-12-09 | 2021-06-17 | Tyme, Inc | Pharmaceutical compositions and methods |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2554246A1 (en) * | 2004-01-29 | 2005-08-11 | Baxter International Inc. | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
WO2006099685A1 (en) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Method for the prophylaxis or treatment of carcinomas |
CN101023940A (en) * | 2006-02-20 | 2007-08-29 | 郝守祝 | Medicine composition of Taxane compounds, preparing method and use |
EP3169707B1 (en) * | 2014-07-11 | 2020-12-02 | The Regents of the University of California | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies |
US9687528B2 (en) * | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
CN109195601A (en) * | 2016-03-15 | 2019-01-11 | 迪美公司 | Pharmaceutical composition for treating cancer |
-
2019
- 2019-07-02 BR BR112021000279A patent/BR112021000279A8/en not_active Application Discontinuation
- 2019-07-02 EA EA202190201A patent/EA202190201A1/en unknown
- 2019-07-02 EP EP19841949.1A patent/EP3820482A4/en not_active Withdrawn
- 2019-07-02 JP JP2021500520A patent/JP2021530482A/en not_active Withdrawn
- 2019-07-02 CN CN201980054337.1A patent/CN112584841A/en active Pending
- 2019-07-02 WO PCT/US2019/040264 patent/WO2020023191A1/en unknown
- 2019-07-02 CA CA3105717A patent/CA3105717A1/en active Pending
- 2019-07-02 KR KR1020217003523A patent/KR20220098082A/en active Search and Examination
- 2019-07-02 AU AU2019309757A patent/AU2019309757A1/en not_active Abandoned
-
2021
- 2021-01-06 PH PH12021550033A patent/PH12021550033A1/en unknown
- 2021-01-07 IL IL280000A patent/IL280000A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3820482A4 (en) | 2022-03-23 |
KR20220098082A (en) | 2022-07-11 |
CN112584841A (en) | 2021-03-30 |
AU2019309757A1 (en) | 2021-03-04 |
BR112021000279A8 (en) | 2021-04-20 |
BR112021000279A2 (en) | 2021-04-06 |
WO2020023191A1 (en) | 2020-01-30 |
CN112584841A8 (en) | 2021-06-18 |
EP3820482A1 (en) | 2021-05-19 |
CA3105717A1 (en) | 2020-01-30 |
EA202190201A1 (en) | 2021-04-09 |
PH12021550033A1 (en) | 2021-09-20 |
JP2021530482A (en) | 2021-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281445A (en) | Therapeutic nanoparticles and methods of use thereof | |
IL276494A (en) | Pediatric niraparib formulations and pediatric treatment methods | |
IL292810A (en) | Therapeutic compounds and methods of use | |
IL280000A (en) | Tumor reduction formulations and methods of use thereof | |
IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
IL265955A (en) | Therapeutic compounds and methods of use thereof | |
IL276687A (en) | Trialkyne linking agents and methods of use | |
IL281438A (en) | Pyridazinones and methods of use thereof | |
ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
IL276135A (en) | Compositions and methods of use | |
IL285928A (en) | Fulvestrant formulations and methods of their use | |
IL272937A (en) | Compositions and methods for the treatment of fibrotic diseases | |
EP3099325A4 (en) | Methods of treating and imaging tumor micrometastases using photoactivatable immunoconjugates | |
EP3870203A4 (en) | Therapeutic combinations of tdfrps and additional agents and methods of use | |
IL286481A (en) | Pyridazinones and methods of use thereof | |
IL291730A (en) | Protein-macromolecule conjugates and methods of use thereof | |
IL283782A (en) | Anellosomes and methods of use | |
IL279633A (en) | Immunoconjugates targeting adam9 and methods of use thereof | |
ZA202207188B (en) | Liquid tasimelteon formulations and methods of use thereof | |
ZA202000502B (en) | Cosmetic compositions and methods of use | |
ZA202108213B (en) | Klebsiella vaccine and methods of use | |
EP3600277A4 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
IL276792A (en) | Inhaler and methods of use thereof | |
IL274433A (en) | Fulvestrant formulations and methods of their use | |
GB2589398B (en) | Compounds and methods of use |